Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) - Total Liabilities
Based on the latest financial reports, Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) has total liabilities worth CN¥842.81 Million CNY (≈ $123.33 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Shanghai Allist Pharmaceuticals Co. Ltd. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Shanghai Allist Pharmaceuticals Co. Ltd. A - Total Liabilities Trend (2017–2025)
This chart illustrates how Shanghai Allist Pharmaceuticals Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Shanghai Allist Pharmaceuticals Co. Ltd..
Shanghai Allist Pharmaceuticals Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Shanghai Allist Pharmaceuticals Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $117.10 Million |
|
STAG Industrial Inc
NYSE:STAG
|
USA | $3.40 Billion |
|
Tencent Music Entertainment Group
F:63TA
|
Germany | €22.72 Billion |
|
Grupo Aeroportuario del Sureste S. A. B. de C. V
MX:ASURB
|
Mexico | MX$41.52 Billion |
|
Yanzhou Coal Mining Company Limited
F:YZC
|
Germany | €291.25 Billion |
|
Alkermes Plc
NASDAQ:ALKS
|
USA | $2.58 Billion |
|
Conagra Brands, Inc.
NYSE:CAG
|
USA | $10.92 Billion |
|
JUSUNG ENGINEERING Co. Ltd
KQ:036930
|
Korea | ₩278.20 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Shanghai Allist Pharmaceuticals Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Shanghai Allist Pharmaceuticals Co. Ltd.'s balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Allist Pharmaceuticals Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Allist Pharmaceuticals Co. Ltd. A (2017–2025)
The table below shows the annual total liabilities of Shanghai Allist Pharmaceuticals Co. Ltd. A from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥-6.50 Billion ≈ $-950.98 Million |
-1126.15% |
| 2024-12-31 | CN¥633.32 Million ≈ $92.67 Million |
+60.65% |
| 2023-12-31 | CN¥394.22 Million ≈ $57.69 Million |
+54.52% |
| 2022-12-31 | CN¥255.12 Million ≈ $37.33 Million |
+62.50% |
| 2021-12-31 | CN¥156.99 Million ≈ $22.97 Million |
+44.02% |
| 2020-12-31 | CN¥109.01 Million ≈ $15.95 Million |
-24.31% |
| 2019-12-31 | CN¥144.02 Million ≈ $21.07 Million |
-52.62% |
| 2018-12-31 | CN¥303.96 Million ≈ $44.48 Million |
+138.64% |
| 2017-12-31 | CN¥127.37 Million ≈ $18.64 Million |
-- |
About Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl c… Read more